Core Viewpoint - FibroBiologics, Inc. has received an extension from a Nasdaq Hearings Panel to regain compliance for continued listing on The Nasdaq Capital Market, providing a clear path for the company to maintain its stock listing [1][2]. Group 1: Compliance Conditions - The company must meet an equity standard of $2.5 million under Nasdaq Listing Rule 5550(b)(1) by February 27, 2026, as an alternative to the $35 million minimum Market Value of Listed Securities under Listing Rule 5550(b)(2) [2]. - FibroBiologics is required to meet the minimum bid price requirement of $1.00 per share by April 13, 2026, as per Nasdaq Listing Rule 5550(a)(2) [2]. - The company must comply with all applicable criteria for continued listing on Nasdaq by April 13, 2026 [2]. Group 2: Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [4]. - The company holds over 270 patents issued and pending in the US and internationally, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [4]. - FibroBiologics represents a new generation of medical advancements in cell therapy and tissue regeneration [4].
FibroBiologics Granted Extension by Nasdaq to Regain Compliance